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Like almost all human cancers, malignant gliomas in the central nervous system are, in essence, a genetic disease (1, 2) , originating from astrocyte-like neural stem cells in the subventricular zone that harbor oncogenic mutations (3) . A tremendous amount of effort has been made toward uncovering the genetic alterations underlying gliomagenesis (4, 5) , especially in the most malignant form-glioblastoma of World Health Organization (WHO) grade IV [see refs (6, 7) for glioma classification and patient demographics]. Somatic mutations target oncogenes and tumor-suppressor genes, whereas 'driver' mutations are positively selected for their ability to confer growth advantage via the acquisition of oncogenic activity concomitant with the inhibition of tumor-suppressive activity, the rest are 'passenger' mutations lacking defined roles (2) .
Accordingly, numerous types of genetic alteration have been identified in glioblastoma (4, 5, 8) . Notably, loss of heterozygosity in chromosome 10q, oncogenic amplification of EGFR (epidermal growth factor receptor) and homozygous deletion or mutation of the tumor-suppressor genes CDKN2A (cyclin-dependent kinase inhibitor 2A) and PTEN (phosphatase and tensin homolog) are found in primary (de novo) glioblastomas, whereas mutations in the tumor-suppressive TP53 are commonly detected in secondary (progressive) glioblastomas derived from diffuse astrocytomas of WHO grade II and grade III (referred to collectively as lower-grade glioma hereafter) (4, 6) . Overall, various genetic alterations converge onto three core pathways in glioblastoma: the oncogenic receptor tyrosine kinase/RAS/ phosphatidylinositide 3-kinase pathway and the two tumorsuppressive TP53 and RB pathways (5) . Although the frequencies of genetic alterations among the core pathways vary between 78 and 88%, recurrent changes in a single gene occur at much lower frequencies ( Table 1) .
functionally required for the interaction with the substrate isocitrate; (ii) IDH1 mutations were found preferentially in younger patients, nearly all with secondary glioblastomas; and (iii) patients with IDH1 mutation had median overall survival three times longer than those without. Subsequent studies not only confirmed the high frequency of IDH1 R132 mutations in secondary glioblastomas (>85%) but also revealed the prevalence in lower-grade gliomas (>68%) (10, 11) (Table 2 ). Among lowergrade glioma with IDH1 mutations, the substitution of Arg132 with histidine-IDH1 R132H -occurred 92% of the time, whereas IDH1 R132C , IDH1 R132G , IDH1 R132S and IDH1 R132L were at much lower frequencies (12) . Lower-grade gliomas without IDH1 mutations often acquired mutations in the mitochondrial IDH2 gene at Arg172 (11) , which is functionally analogous to IDH1 Arg132 (13) . Overall, 95% of these mutations were identified in IDH1 and only 5% in IDH2 (11, 14) (Table 2) . Thus, IDH1 mutations will be discussed hereafter with IDH1 R132H as the archetype.
It is noteworthy that IDH1 R132H is rare in primary glioblastomas (<5%) and non-existent in other types of brain tumors (10, 11) . Furthermore, IDH1 and IDH2 mutations are rare or non-existent in cancer types outside of the central nervous system (11, 15, 16) , with the exception of cartilaginous tumors, leukemia and lymphoma, and intrahepatic cholangiocarcinomas (17, 18) (Table  2) . Importantly, IDH1 R132H confers a distinctive survival advantage in glioma patients; large cohort studies confirmed a 2-fold increase of median overall survival in glioblastoma patients and a more than threefold increase in lower-grade glioma patients compared with their respective controls (11, 19) . Furthermore, multivariate analysis confirmed that IDH1 R132H was an independent favorable prognostic marker in gliomas (20) . Moreover, maximal resection or combined temozolomide with radiotherapy confers survival benefit specifically on patients with IDH1 R132H astrocytomas without 1p/19q codeletion but not those with 1p/19q codeletion or IDH1 wild-type gliomas (21) .
IDH1 mutation is neomorphic
The vast majority of somatic mutations in cancer genes are dominantly acting, i.e., a single-allele mutation is sufficient to be oncogenic, whereas inactivation of tumor-suppressor genes often requires mutation of both alleles (2) . The IDH1 enzyme catalyzes the conversion of isocitrate and NADP + to 2-oxoglutarate and NADPH (Figure 1a ). Given the heterozygous nature of IDH1 R132H , a feed-forward mechanism was initially speculated by which the mutation abrogates the negative feedback to increase NADPH production (22) because NADPH is a reducing equivalent critical for biosynthesis and redox homeostasis (23) . Consistent with its role in glioma growth, IDH1 was found to be overexpressed in glioblastoma and essential to tumor growth (24) . However, the fact that IDH1 R132H is associated with decreased NADPH production (11, (25) (26) (27) (28) (29) apparently argues against this notion.
Gene mutations in the mitochondrial succinate dehydrogenases and fumarate hydratase of the citric acid cycle have been linked to paraganglioma and leiomyosarcoma, respectively (30) . These loss-of-function mutations result in respective accumulation of succinate and fumarate, which inhibits the 2-oxoglutarate-dependent HIF (hypoxia-inducible factor) prolyl 4-hydroxylases (EGLN) that negatively regulate HIF-1-a transcription factor implicated in tumor angiogenesis and glycolysis (31) (Figure 1b ). Thus, the notion that IDH1 R132H is a loss-of-function mutation was proposed based on the dominant IDH1 R132H inhibition of wild-type IDH1 catalytic activity through heterodimerization, thereby reducing the production of 2-oxoglutarate and in turn enhancing HIF-1 activity (32) . Subsequent studies confirmed the heterodimeric interaction but questioned the dominant-negative effect of IDH1 R132H and the stimulation of HIF-1 signaling in gliomas (33, 34) .
Lastly, a landmark discovery established that IDH1 R132H is, in fact, neomorphic, resulting in a dominant gain-of-function that catalyzes the NADPH-dependent reduction of 2-oxoglutarate to (D)-2-hydroxyglutarate [D-2HG or R-2HG] but not the enantiomer L-2HG or S-2HG (35) (Figure 1a ). Furthermore, IDH1 R132H gliomas generally had up to 100-fold higher levels of D-2HG than those without the mutation. Similarly, high D-2HG levels were also detected in the tumor tissues and sera of leukemia patients with IDH1 and IDH2 mutations (13) . Therefore, IDH1 R132H acquires a neomorphic enzymatic activity to produce D-2HG.
D-2HG induces epigenetic reprogramming
D-2HG is a competitive inhibitor of multiple 2-oxoglutaratedependent dioxygenases, including EGLN, histone demethylases and the TET (ten-eleven translocation) family of 5-methylcytosine hydroxylases (36) (Figure 1a ). In particular, histone demethylases are 200-fold more sensitive to D-2HG than EGLN, suggesting the involvement of IDH1 R132H in chromatin remodeling (37) . Indeed, exogenous IDH1 R132H induced impairment of histone demethylation apparently preceding DNA hypermethylation (38) . The greater accumulation of a repressive mark-trimethylation of lysine 9 in histone 3 (H3K9me3)-was particularly noticeable in preceding the changes in DNA methylation, resulting from specific inhibition of the demethylase KDM4C ( Figure 1a ). In endogenous IDH1 R132H -heterozygous cells, global and gene-specific H3K9me3 correlated with locus-specific DNA hypermethylation of downregulated genes (39) . Furthermore, AGI-5198-a potent IDH1 R132H inhibitor-induced demethylation of histone H3K9me3 and expression of genes associated with differentiation in endogenous IDH1 R132H glioma cells (40) . Similarly, AGI-6780-a potent inhibitor of IDH2 R140Q -induced differentiation of leukemia cells (41) . Therefore, D-2HG induces histone methylation and blocks cell differentiation.
Likewise, exogenous IDH1 R132H was sufficient to induce DNA hypermethylation in immortalized primary human astrocytes in a pattern resembling the glioma-CpG island methylator phenotype (G-CIMP) (42) (Figure 1a )-an associated feature of gliomas harboring IDH1 mutations (43) . Genetically engineered heterozygous IDH1 R132H in human colon cancer HCT116 cells and SV40immortalized human astroglial cells also induced genome-wide (39, 44) . The TET 5-methylcytosine hydroxylases catalyze the oxidation of 5-methylcytosine into 5-hydroxymethylcytosine (5hmC), thereby maintaining gene promoters in an unmethylated state for gene activation (45) . Although exogenous IDH1 R132H was shown to inhibit the 5-methylcytosine hydroxylase activity and reduce 5hmC conversion (36, 42) , the relationship between IDH1 R132H and 5hmC in glioma remains controversial (36, 46, 47) . In fact, 5hmC depletion was found in many types of human cancer (46, 48) and was associated with poor survival of glioma patients (47, 49) . Hence, IDH1 R132H induces G-CIMP-like epigenetic reprogramming, but its involvement in 5hmC depletion remains less clear in glioma.
Is IDH1 mutation oncogenic?
IDH1 R132H is believed to drive gliomagenesis through the 'oncometabolite' D-2HG to induce epigenetic, metabolic and transcriptional alterations (17, 18, 22, 50) . There is abundant, albeit circumstantial, evidence to support this concept. First, IDH1 R132H is recurrent and neomorphic, supporting a gain of function in a proto-oncogene. Second, IDH1 R132H is believed to be an early genetic event that confers a growth advantage for glioma initiation (19, 51) . Third, IDH1 R132H is genetically preserved in recurrent gliomas (52) (53) (54) . Fourth, exogenous IDH1 R132H is sufficient to induce G-CIMP, block cell differentiation, and initiate oncogenic transformation (34, 38, 42) . Finally, potent IDH1 inhibitors were shown to promote differentiation, inhibit tumor growth and extend animal survival (40, 55) . The fact that these inhibitors are in clinical trials epitomizes the rapid biomedical advancements from concept to bedside since the seminal discovery of IDH1 mutations.
Cautionary observations
Although the ongoing clinical trials hold the promise of eventual reduction of morbidity and mortality, the optimism of success has yet to be reconciled with indisputable clinical and experimental observations that seem to suggest caution. First, despite its prevalence in glioma, heterozygous IDH1 R132H is scarcely preserved in cell culture or patient-derived xenografts (56) (57) (58) (59) . As such, exogenous IDH1 R132H has almost become the norm of investigation (34, 38, 40, 42, 55, 60) ; however, none of the resultant findings have been corroborated in endogenous IDH1 R132H -heterozygous models (26, 29, 44, 61, 62) (Table 3) . Second, the notion that IDH1 R132H is oncogenic is based on the comparison of exogenous IDH1 R132H with wild-type IDH1, which seems at odds with the observation that patients with IDH1 R132H glioma have better survival than those of IDH1-wild type (9, 11, 19, 20) . Third, in agreement with the lack of tumor development in heterozygous Idh1 R132H mice despite high levels of D-2HG (26, (61) (62) (63) , patients with D-2-hydroxyglutaric aciduria-a rare autosomal recessive disorder characterized by high D-2HG levels in urine, plasma, and cerebrospinal fluidhave no predisposition to tumor development. These patients may have IDH2 R140Q and IDH2 R140G in the germline and are either asymptomatic or manifest encephalopathy, muscular dystrophy and cardiomyopathy (64, 65) . Consistently, IDH2 R140Q and IDH2 R172K transgenic mouse models recapitulated cardiomyopathy and neurodegeneration with no tumor development (66) . Of note, L-2-hydroxyglutaric aciduria-another rare autosomal recessive encephalopathy-apparently confers predisposition to brain malignant tumors (67) . Finally, studies have indicated that D-2HG is non-essential to glioma progression (29, 68, 69) . Therefore, these observations not only challenge the concept that IDH1 R132H is gliomagenic but also call into question the potential efficacy of mutant IDH inhibitors in glioma treatment.
IDH1 mutation-guilty by association
The assessment of IDH1 R132H in relation to TP53 mutation or loss of 1p/19q by comparing the initial and recurrent biopsies from the same individuals suggested that IDH1 R132H precedes the other known genetic events and is therefore an early event in the development of lower-grade gliomas (51) . Integrated genomic analysis further indicated that the expression of IDH1 R132H protein preceded the production of mutant p53 protein and copynumber alterations of PTEN and EGFR in secondary glioblastoma (76) . Further longitudinal analysis showed that IDH1 R132H was the only event shared in both initial and recurrent gliomas (52, 54) , although multiregional and temporal samplings revealed additional shared events, including TERT promoter mutation and loss of 1p/19q in one case and TP53 mutation in another (53) . Thus, IDH1 R132H is implicated in glioma initiation and progression, thanks to its tight association. However, this gliomagenic notion is at odds with the lack of glioma development in both heterozygous Idh1 R132H mice (26, 61, 62) and D-2-hydroxyglutaric aciduria patients (64) . Although genetic events including inactivation of TP53 and/or activation of oncogenic signaling, e.g., platelet-derived growth factor (PDGF), are sufficient to induce glioma, IDH1 R132H has been shown to inhibit glioma penetrance and extend animal survival in comparison with wild-type IDH1 (62,72-74). Furthermore, the importance of IDH1 R132H heterozygosity cannot be overemphasized because IDH1 R132H requires a wild-type allele to produce D-2HG, whereas loss of IDH1 R132H heterozygosity essentially eliminates D-2HG production (29, 77, 78) . Likewise, genetic alterations at the IDH1 locus, including IDH1 R132H amplification, engendered allelic imbalance between IDH1 and IDH1 R132H , thereby diminishing D-2HG production in recurrent gliomas (69) . Therefore, loss of IDH1 R132H heterozygosity and IDH1 allelic imbalance result in non-functional IDH1 R132H in association with glioma recurrence and progression ( Figure 2 ).
Does IDH1 mutation-induced epigenetic reprogramming drive gliomagenesis?
DNA hypermethylation has been shown to compromise binding of the methylation-sensitive insulator protein CTCF (CCCTC-binding factor) in IDH-mutant gliomas, resulting in loss of insulation of a neighboring enhancer and aberrant upregulation of the receptor tyrosine kinase gene PDGFRA (79) . A modest increase of PDGFRA transcripts was also observed in IDH-mutant glioma when compared with IDH-wild-type glioma (80) . Furthermore, 5hmC enrichment in gene body regions correlated significantly with the upregulation of genes, such as LGR5 (leucine-rich repeat-containing G-proteincoupled receptor 5), in IDH-mutant glioma (81) . It remains unclear, however, whether these epigenetic targets are essential to IDH-mutant gliomagenesis.
In contrast, IDH-mutant gliomas with high levels of DNA methylation had more favorable clinical outcomes than those with low levels (82) . A high-to low-level shift in DNA methylation has been identified during glioma recurrence, giving rise to an IDH-wild-type-like glioblastoma phenotype (83) . Thus, the loss of DNA methylation is associated with glioma progression. Likewise, silencing of epigenetic targets, such as LDHA (lactate dehydrogenase A), RBP1 (retinol-binding protein), MIR148A (microRNA 148a) and F3 (coagulation factor III, tissue factor), was associated with reduced malignant growth and favorable outcome in IDH-mutant gliomas (59, (84) (85) (86) . Thus, there is insufficient evidence that IDH1 R132H -induced epigenetic reprogramming drives gliomagenesis. Does IDH1 mutation increase cell proliferation?
Exogenous IDH1 R132H was first shown to stimulate proliferation of late-passaged human astrocytes with inactivated TP53 and RB signaling (87) in reference to wild-type IDH1 (34) . The increased proliferation involved D-2HG stimulation, rather than inhibition (Figure 1a ), of EGLN activity and in turn downregulation of HIF signaling as part of cell transformation (34) . However, the effect of IDH1 R132H on hypoxic signaling seems debatable; whereas reduced HIF signaling was observed in IDH-mutant gliomas (59, 88, 89) , increased HIF-1α abundance and target gene expression were also reported in IDH-mutant gliomas and mouse brain-specific Idh1 R132H knock-in cells (26, 32) . With respect to cell proliferation, a large body of evidence indicates that IDH1 R132H inhibits glial cell proliferation (72, (90) (91) (92) (93) . Mechanistically, D-2HG inhibits ATP synthase, resulting in decreased mTOR (mammalian target of rapamycin) signaling and cell growth (94) . Likewise, D-2HG-mediated ATP depletion activates AMPK (5′ AMP-activated protein kinase), thereby inhibiting protein synthesis and mTOR signaling in glioma cells (95) . Furthermore, D-2HG promotes cell-cycle arrest by inhibiting the FTO (fat mass and obesity-associated) demethylase activity, thereby increasing N 6 -methyladenosine modification of MYC/CEBPA (CCAAT/enhancer binding protein alpha) transcripts for destabilization and, in turn, decreasing proliferative signaling (93) . Moreover, engineered heterozygous IDH1 R132H significantly inhibited glial cell proliferation by targeting YAP (Yes-associated protein) and Notch pathways (44) . Collectively, these studies provide strong evidence that IDH1 R132H targets various signaling pathways to inhibit glial cell proliferation at least in vitro.
Antagonism between heterozygous IDH1 mutation and anchorage-independent growth
The cellular ability to proliferate in anchorage-independent growth is consistently associated with tumorigenicity (96) . Accordingly, exogenous IDH1 R132H has been shown to increase anchorage-independent growth of immortalized human astrocytes compared with wild-type control (34, 42, 60, 70, 71) (Table  3) . Likewise, exogenous IDH1 R132H resulted in spheroid growth of MYC-immortalized human neural progenitor cells (61) . Additional evidence includes the upregulation of neural stemcell marker genes including NES (nestin) in IDH1 R132H -transduced, late-passaged astrocytes (38, 42) , albeit under anchoragedependent conditions. Apparently, these findings support the notion that IDH1 R132H is gliomagenic; it is unclear, however, whether the exogenous IDH1 R132H remained expressed in the transduced cells during anchorage-independent growth (see below).
It is striking, however, that none of the abovementioned findings are reproduced in IDH1 R132H -heterozygous cells; in fact, heterozygous Idh1 R132H apparently prevented spheroid growth of neural progenitor cells (61) . In keeping with this, heterozygous IDH1 R132H suppressed anchorage-independent growth of glioma cells whereas hemizygous IDH1 R132H (deficient in wild-type IDH1 allele) lost the suppression (29) (Table 3) . Conversely, anchorageindependent but not anchorage-dependent conditions selected against IDH1 R132H heterozygosity via a non-genetic mechanism (29) (Figure 2 ). This antagonism between IDH1 R132H heterozygosity and anchorage-independent growth not only underscores the functional importance of IDH1 R132H heterozygosity in glioma biology but also provides an explanation for the frequent loss of either wild-type or mutant IDH1 allele in patient-derived xenograft, ex vivo spheroid culture, and glioma recurrence (57, 59, 69, 77, 97) . Furthermore, NES was strikingly upregulated in anchorage-independent culture of IDH1 R132H -hemizygous cells compared with IDH1 R132H -heterozygous cells (P.D.B.Tiburcio et al., unpublished data). Consistently, NES expression was significantly higher in IDH-wild-type gliomas than in IDH-mutant gliomas (P.D.B.Tiburcio et al., unpublished data), in agreement with the observation that nestin is an adverse predicator of lower-grade gliomas (98) . Therefore, heterozygous IDH1 R132H is tumor suppressive by inhibiting NES expression and anchorageindependent growth. Conversely, anchorage-independent growth selects against IDH1 R132H heterozygosity, rendering IDH1 R132H non-functional.
Inactivation of the TP53 and RB pathways renders IDH1 mutation non-functional
The antagonism between IDH1 R132H heterozygosity and anchorage-independent growth was also observed in mouse transplantation models, especially in a genetic background without engineered inactivation of tumor-suppressor gene(s), giving rise to tumor growth but no expression of exogenous IDH1 R132H (72) . Exogenous IDH1 R132H expression was noticeably enhanced when the TP53 and/or RB pathways became deficient (71) (72) (73) . It is noteworthy that homozygous Cdkn2a deletion (affecting both TP53 and RB pathways) resulted in strong IDH1 R132H staining in gliomas but complete loss of IDH1 R132Hassociated survival advantage (73) , which was also observed with the homozygous deletion of Cdkn2a and/or Pten in glioma (75) . Given the functional requirement of IDH1 mutation for survival advantage, inactivation of the tumor-suppressor genes renders IDH1 R132H permissible but non-functional ( Figure 2b ). As such, the inactivation of both TP53 and RB pathways, e.g., in the immortalized human astrocytes (87), might have obscured IDH1 R132H tumor-suppressive activity (34, 42, 60, 70, 71) . Moreover, IDH1 R132H -associated DNA repair defects and genetic instability (99-101) might have also been relevant, especially in those 'latepassaged' cells (34, 42, 60) .
Extracellular glutamate negates the tumorsuppressive effect of IDH1 mutation IDH1 R132H malignant glioma arises predominantly from the frontal lobe (76) , where the hominoid-specific GLUD2 (glutamate dehydrogenase 2) gene is evolutionarily selected for the degradation of high flux of glutamate neurotransmitter (102, 103) . Extracellular metabolites have been shown to negate IDH1 R132H suppression of anchorage-independent growth (29,72) (P.D.B.Tiburcio et al., unpublished data) ( Figure 2b ). IDH1 R132H cells apparently maintain redox homeostasis by increasing glutathione synthesis through the trans-sulfuration pathway and the reliance on glutaminolysis (28, 104) . In comparison with IDH1 R132H -heterozygous cells, IDH1 R132H -hemizygous cells exhibited higher NADPH levels and glutathione/oxidized glutathione ratio (29) . It has been proposed that IDH-mutant gliomas depend on glutamate and lactate to alleviate metabolic stress (105, 106) . Consistently, the addition of glutamate reversed IDH1 R132H inhibition of PDGF-driven proliferation of neural progenitor cells (92) . Likewise, the addition of N-acetyl cysteine or glutamate markedly increased anchorage-independent growth of IDH1 R132H -heterozygous glioma cells (29,72) (P.D.B. Tiburcio et al., unpublished data) . The overpowering effect of glutamate was corroborated by the differential effects of IDH1 R132H on tumorigenesis between the glutamate-rich cerebral cortex and the subcutaneous tissue in Trp53 +/+ mice; exogenous IDH1 R132H was virtually ineffective in inhibiting PDGF-driven gliomagenesis in the brain but potently effective in blocking subcutaneous tumor growth (72) . Therefore, glutamate may be particularly pertinent to IDH1 R132H prevalence in glioma but not in most other cancer types (10, 11, 15, 16) . Together, these studies indicate the importance of extracellular glutamate for IDH1 R132H glioma growth.
IDH1 mutation does not initiate gliomagenesis by itself
As discussed above, no glioma development has been seen in heterozygous Idh1 R132H mice (26, 61, 62) or in patients with D-2-hydroxyglutaric aciduria (64) . Of note, these mice exhibited disorganization of the subventricular zone and epigenetic and transcriptional profiles resembling those of IDH-mutant glioma (61, 62) . In combination with other genetic events, heterozygous Idh1 R132H reduced the penetrance of Trp53 deletioninduced glioma by 70% and extended survival compared with wild-type Idh1 (62) . Likewise, glioma models driven by PDGF in combination with Trp53 knockdown revealed survival benefits of IDH1 R132H in RCAS/tva mice (73) . Finally, IDH1 R132H obliterated PDGF-induced gliomagenesis in RCAS/tva mice when selection against exogenous IDH1 R132H was precluded, demonstrating IDH1 R132H innate ability for tumor suppression (72) (Figure 2a ). Thus, IDH1 R132H neither initiates nor promotes gliomagenesis.
Studies relying on exogenous IDH1 R132H expression in TP53/ RB-deficient human astrocytes have come to a divergent view ( Table 3 ). Exogenous IDH1 R132H was shown to overcome telomereinduced crisis by activating TERT expression, thereby leading to cell transformation and tumor growth (71) . Likewise, long-term IDH1 R132H expression impaired contact inhibition and yielded intracranial lesions with parenchymal infiltration (60) . Moreover, IDH1 R132H in comparison with IDH1 shortened mouse survival in a combined Atrx −/− , Cdkn2a −/− and Pten −/− background of PDGFdriven glioma models (75) . The biological relevance of these studies, however, is less clear because mutations in CDKN2A and PTEN are rare in IDH-mutant gliomas (19) . Furthermore, IDH1 R132H -induced hydrocephalic neuropathy (26, 61, 62, 66) , hypoxic induction of oncogenic L-2HG (107,108) and IDH1 R132Hassociated genetic instability (99-101) might have complicated the interpretations of the studies.
Is IDH1 mutation a therapeutic target in glioma?
The therapeutic potential of IDH1 and IDH2 mutations has been explored extensively; different classes of mutant IDH1 and IDH2 inhibitors have been developed for ongoing phase 1 or phase 1/2 clinical trials of mostly hematological diseases and some solid tumors (109, 110) . The outcome of these inhibitors in glioma-associated survival studies in mouse models, however, seems less promising; the efficacies vary from modest or indifferent to detrimental despite their high potencies in inhibiting D-2HG production and inducing cell differentiation. AGI-5198 was first shown to decrease subcutaneous growth of IDH1 R132H glioma cells (40) , but tumor regression was not reproduced in another study despite near-complete inhibition of 2HG (111) . Likewise, an IDH1 R132H/C -specific inhibitor (IDHi) (112) had near-complete 2HG elimination but showed no survival benefits in orthotopic transplantation of IDH1 R132H glioblastoma cells (113) . In fact, long-term exposure to IDHi prior to orthotopic transplantation significantly shortened survival (113) . The brain-penetrant IDH1 R132H inhibitors MRK-A and MRK-B prolonged survival in orthotopic transplantation of one IDH1 R132H glioma cell type but not another (114) . Finally, BAY 1436032-an orally available, pan-IDH1 R132X inhibitorsignificantly but modestly extended survival in intracranial IDH1 R132H -astrocytoma transplantation (55) . Collectively, mutant IDH1 inhibitors may have therapeutic effects on glioma independent of D-2HG depletion. The first-in-human phase I study (NCT03030066) involving 45 patients with recurrent/ progressive IDH1 mutant glioma has shown favorable tolerance and brain distribution with the pan-IDH1 R132X inhibitor DS-1001b (115) . Of the 38 evaluable patients in this ongoing trial, 17 (45%) achieved stable disease, 3 (8%) partial response, 2 (5%) minor response, and 1 (3%) complete response.
Of note, mutant IDH1 inhibitors have undesired effects that diminish the efficacy of chemotherapy and radiation therapy. AGI-5198 was shown to reduce radiosensitivity through restoration of NADPH levels, thereby protecting IDH1-mutant cells against ionizing radiation (27) . It also desensitized cisplatin killing of IDH1-mutant cells by reducing levels of reactive oxygen species (116) and completely reversed the sensitivity of cancer cells to poly(adenosine 5′-diphosphate-ribose) polymerase inhibitors (101) . In light of the association of non-functional IDH1 R132H with glioma progression and recurrence, as discussed above, additional biochemical, metabolic and immunological targets should be explored [reviewed in ref. (110) ] for the development of better treatment. Likewise, investigating the mechanisms that negate IDH1 R132H suppression of gliomagenesis ( Figure  2 ) may provide novel targets.
Concluding remarks
IDH1 R132H heterozygosity and its association with better survival are hallmarks of gliomas compared with those without the mutation. Whether IDH1 R132H is a 'friend or foe' depends principally on the model system employed. Studies with heterozygous IDH1 R132H model systems have demonstrated that IDH1 R132H is neither a driver nor a passenger but beneficial-another category of somatic mutations in cancer (80) . The beneficial effect of heterozygous IDH1 R132H in comparison with IDH1-wild-type or loss of IDH1 R132H heterozygosity is supported by both clinical and experimental findings discussed above. In contrast, the oncogenic IDH1 R132H theory is predicated exclusively on the findings of exogenous IDH1 R132H expression where the selection against IDH1 R132H heterozygosity by anchorage-independent growth has essentially been overlooked. Despite being intrinsically tumor suppressive, IDH1 R132H activity can be undermined by various intracellular and extracellular factors, notably inactivation of tumor-suppressor genes, IDH1 R132H allelic imbalance and selection against IDH1 R132H heterozygosity, and extracellular glutamate and reducing equivalents. The functional, rather than genetic, loss of IDH1 R132H provides an explanation for the prevalence and preservation of IDH1 R132H from glioma initiation to progression. It is imperative, therefore, that investigations be directed toward understanding the mechanism by which IDH1 R132H functionality is negated for better prevention and therapeutic intervention of glioma progression.
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